Clinical Trials at Dana-Farber Cancer Institute

As of August 2026, 341 paid clinical trials are recruiting at Dana-Farber Cancer Institute, located at 44 BINNEY ST, BOSTON, MA 02115-6013, phone (617) 632-3497 in Boston, Massachusetts. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

View the full facility profile →

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 27, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

342 clinical trials at Dana-Farber Cancer Institute

·Clear filters·

Get a weekly email when new trials open in Boston, MA.

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

Sites in Boston, Newton +19 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07090499·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Drug: Bevacizumab

Sites in Boston +16 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06820463·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

for Advanced Solid Tumor

Drug: AI-081

Sites in Boston +20 more locations

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT06635785·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma Refractory

Sites in Boston +19 more locations

Sponsor: CellCentric Ltd.

Sex: All·Age: 18+

Code: NCT07096778·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

for Metastatic Solid Tumor

Sites in Boston +15 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06561685·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

for Breast Neoplasms

Sites in Boston +8 more locations

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05386108·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Sites in Boston +24 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06899126·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

Sites in Boston +16 more locations

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

for HR+ Breast Cancer

Sites in Boston +17 more locations

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07029399·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for Multiple Myeloma

Sites in Boston +14 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06121843·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for B-cell Acute Lymphoblastic Leukemia

Sites in Boston +16 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 25

Code: NCT06395103·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

for AML, Adult

Sites in Boston +10 more locations

Sponsor: Stelexis BioSciences

Sex: All·Age: 18+

Code: NCT06533761·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

for Lymphoma

Sites in Boston +13 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT07015242·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

Sites in Boston +16 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Boston +14 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06997029·Phase 1·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

for Mature B-Cell Non-Hodgkin Lymphoma

Drug: Glofitamab

Sites in Boston +9 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 6 Months - 30

Code: NCT05533775·Phase 1, Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

for Small Cell Lung Cancer (SCLC)

Sites in Boston +14 more locations

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05652686·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

for Glioblastoma (GBM)

Sites in Boston +16 more locations

Sponsor: Diakonos Oncology Corporation

Sex: All·Age: 18+

Code: NCT06805305·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Boston +9 more locations

Sponsor: Ensem Therapeutics

Sex: All·Age: 18+

Code: NCT06993844·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

for Solid Tumors With HRAS Alterations

Sites in Boston +21 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06026410·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

for Multiple Myeloma

Sites in Boston +10 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06953960·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

for Relapsed/Refractory Non-Hodgkin Lymphoma

Sites in Boston +9 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06090539·Phase 1, Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

for NSCLC (Advanced Non-small Cell Lung Cancer)

Sites in Boston +23 more locations

Sponsor: BlossomHill Therapeutics

Sex: All·Age: 18+

Code: NCT06706076·Phase 1, Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

for Extensive Stage Small Cell Lung Cancer

Drug: Tarlatamab

Sites in Boston +12 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 90

Code: NCT07037758·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

Sites in Boston +16 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06040541·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

for Platinum-resistant Ovarian Cancer

Sites in Boston +8 more locations

Sponsor: Context Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06515613·Phase 1·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

for Carcinoma, Non-Small-Cell Lung

Drug: Navlimetostat

Sites in Boston +11 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06855771·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study of PYX-201 in Advanced Solid Tumors

for Solid Tumor

Sites in Boston +16 more locations

Sponsor: Pyxis Oncology, Inc

Sex: All·Age: 18+

Code: NCT05720117·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for PDAC

Sites in Boston +17 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06922591·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

for Advanced Solid Tumor Cancer

Drug: ABBV-CLS-484

Sites in Boston +12 more locations

Sponsor: Calico Life Sciences LLC

Sex: All·Age: 18+

Code: NCT04777994·Phase 1·Recruiting·Listed Mar 2021

Apply to this trial

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Boston +10 more locations

Sponsor: Pyxis Oncology, Inc

Sex: All·Age: 18+

Code: NCT06795412·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

for Advanced Or Metastatic Merkel Cell Carcinoma

Sites in Boston +17 more locations

Sponsor: TuHURA Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT06947928·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

for Advanced Solid Tumor

Sites in Boston +11 more locations

Sponsor: DualityBio Inc.

Sex: All·Age: 18+

Code: NCT05785741·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

for Breast Cancer

Sites in Boston +14 more locations

Sponsor: Incyclix Bio

Sex: All·Age: 18+

Code: NCT05735080·Phase 1, Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

for Myelodysplastic Syndromes

Drug: Venetoclax

Sites in Boston +21 more locations

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04256317·Phase 2, Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for Advanced Solid Tumors With KRAS G12C Mutations

Sites in Boston +11 more locations

Sponsor: Frontier Medicines Corporation

Sex: All·Age: 18+

Code: NCT06244771·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

for Chronic Lymphocytic Leukemia

Sites in Boston +19 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06876649·Phase 4·Recruiting·Listed Mar 2025

Apply to this trial

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

for Chronic Lymphocytic Leukemia

Sites in Boston +15 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06876662·Phase 4·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

for Relapsed and/or Refractory Multiple Myeloma

Sites in Boston +12 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06153251·Phase 1·Recruiting·Listed Dec 2023

Apply to this trial

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

for Chronic Lymphocytic Leukemia (CLL)

Drug: Venetoclax

Sites in Boston +10 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT04895436·Phase 2·Recruiting·Listed May 2021

Apply to this trial